These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8830064)

  • 1. Haloperidol dose and blood level variability: toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting.
    Darby JK; Pasta DJ; Dabiri L; Clark L; Mosbacher D
    J Clin Psychopharmacol; 1995 Oct; 15(5):334-40. PubMed ID: 8830064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Dose Reduction in Schizophrenia (DORIS) Study: a final report.
    Hirschowitz J; Hitzemann R; Piscani K; Burr G; Frecska E; Culliton D; Mann M; Curtis C
    Schizophr Res; 1997 Jan; 23(1):31-43. PubMed ID: 9050126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma haloperidol and reduced haloperidol concentrations in a geriatric population.
    Chang WH; Jann MW; Chiang TS; Lin HN; Hu WH; Chien CP
    Neuropsychobiology; 1996; 33(1):12-6. PubMed ID: 8821369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients.
    Hesslinger B; Normann C; Langosch JM; Klose P; Berger M; Walden J
    J Clin Psychopharmacol; 1999 Aug; 19(4):310-5. PubMed ID: 10440457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large variations of plasma levels during maintenance treatment with depot neuroleptics.
    Tuninger E; Levander S
    Br J Psychiatry; 1996 Nov; 169(5):618-21. PubMed ID: 8932892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of the clinical utility of radioreceptor assay in outpatients with schizophrenia receiving high doses of neuroleptics.
    Gagné MA; Cormier H; Leblanc G; Lévesque D; Di Paolo T
    Can J Psychiatry; 1993 Oct; 38(8):534-40. PubMed ID: 7902199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interindividual variation in bromperidol metabolism and relationship to therapeutic effects.
    Someya T; Muratake T; Hirokane G; Shibasaki M; Shimoda K; Takahashi S
    J Clin Psychopharmacol; 2000 Apr; 20(2):175-80. PubMed ID: 10770455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia. With particular reference to drug resistance.
    Altamura AC
    Schizophr Res; 1993 Jan; 8(3):187-98. PubMed ID: 8094628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics.
    Khot V; DeVane CL; Korpi ER; Venable D; Bigelow LB; Wyatt RJ; Kirch DG
    J Clin Psychopharmacol; 1993 Apr; 13(2):120-7. PubMed ID: 8463444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A loading-dose strategy for converting from oral to depot haloperidol.
    Ereshefsky L; Toney G; Saklad SR; Anderson C; Seidel D
    Hosp Community Psychiatry; 1993 Dec; 44(12):1155-61. PubMed ID: 7907570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haloperidol: therapeutic window in schizophrenia.
    Palao DJ; Arauxo A; Brunet M; Bernardo M; Haro JM; Ferrer J; Gonzalez-Monclus E
    J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose treatment with haloperidol: the effect of dose reduction.
    Volavka J; Cooper TB; Czobor P; Lindenmayer JP; Citrome LL; Mohr P; Bark N
    J Clin Psychopharmacol; 2000 Apr; 20(2):252-6. PubMed ID: 10770466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective clinical response at low plasma levels of haloperidol in Japanese schizophrenics with acute psychotic state.
    Jibiki I; Kubota T; Fujimoto K; Sakamoto H; Hasegawa M; Furuta H; Yamaguchi N
    Jpn J Psychiatry Neurol; 1993 Sep; 47(3):627-9. PubMed ID: 8301878
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients.
    Jann MW; Crabtree BL; Pitts WM; Lam YW; Carter JG
    Neuropsychobiology; 1997; 36(1):32-6. PubMed ID: 9211442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables.
    Lane HY; Chang WH; Chang YC; Hu OY; Lin HN; Jann MW; Hu WH
    Psychiatry Res; 1997 Sep; 72(2):127-32. PubMed ID: 9335203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological profile of risperidone.
    Ereshefsky L; Lacombe S
    Can J Psychiatry; 1993 Sep; 38 Suppl 3():S80-8. PubMed ID: 7504573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low- and standard-dose depot haloperidol combined with targeted oral neuroleptics.
    Huttunen MO; Tuhkanen H; Haavisto E; Nyholm R; Pitkänen M; Raitasuo V; Romanov M
    Psychiatr Serv; 1996 Jan; 47(1):83-5. PubMed ID: 8925352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia.
    Reschke RW
    Dis Nerv Syst; 1974 Mar; 35(3):112-5. PubMed ID: 17894080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group.
    Peuskens J
    Br J Psychiatry; 1995 Jun; 166(6):712-26; discussion 727-33. PubMed ID: 7545060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lowest effective dose of depot neuroleptics.
    Hoencamp E; Haffmans PJ; Jansen GS
    Br J Psychiatry; 1992 Mar; 160():422-3. PubMed ID: 1348655
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.